Hans Layman: New Insights into Selective T-Cell Activation from the START-001 Trial
Hans Layman/LinkedIn

Hans Layman: New Insights into Selective T-Cell Activation from the START-001 Trial

Hans Layman, Strategic Advisor at ASPIRE, Executive Director, Oncology at Meso Scale Diagnostics, shared on LinkedIn:

“Exciting new findings in Nature Medicine from Marengo Therapeutics on invikafusp alfa, a first-in-class bispecific T-cell agonist.

What I find particularly interesting is the approach to selective T-cell activation, rather than broadly stimulating the immune system. By targeting Vβ6/Vβ10 T-cell subsets and providing IL-2 receptor agonism, invikafusp offers a differentiated strategy for cancer immunotherapy.

The early clinical findings are encouraging, with responses observed in heavily pretreated patients, including those with checkpoint inhibitor-resistant colorectal and lung cancers.

What really stands out to me is the PK/PD relationship. Increasing drug exposure did not necessarily translate into greater biological activity. Instead, integrating PK, immune activation, and safety data supported selecting an optimal biological dose rather than simply escalating to the maximum tolerated dose.

It’s great to see Meso Scale Discovery technology supporting this work through quantitative PK assays, soluble CD25 measurements, and multiplex cytokine profiling.

Congratulations to Zhen Su and the Marengo team, along with Aurélien Marabelle, François-Xavier Danlos, Italiano Antoine, Ryan Sullivan, and their collaborators!”

Title: Bispecific dual T cell agonist invikafusp alfa in solid tumors: the phase 1/2 START-001 trial

Authors: Ryan J. Sullivan, Nicholas P. Tschernia, Claire F. Friedman, Mercedes Herrera, Guru P. Sonpavde, Kai He, Antoine Italiano, Aurélien Marabelle, Matthieu Roulleaux-Dugage, François-Xavier Danlos, Elena Garralda Cabanas, Alberto Hernando-Calvo, Manuel Pedregal, Aparna Parikh, Gopakumar Iyer, Ahmed Zakari, E. John Wherry, Jeffrey Schlom, Renee N. Donahue, Shannon McCue, Sharon Cross, Karunya Srinivasan, Lisa Benincosa, Madan Katragadda, Zhenming Shun, Kevin Chin, Zhen Su, Ke Liu, Lillian L. Siu, James L. Gulley

Read the full article.

You may also be interested in: